CT colonography tattles on false negatives in colonoscopy

Colonoscopy misses or misjudges a substantial percentage of polyps that CT colonography can correctly flag as problematic, a study at the University of Wisconsin suggests.

In a retrospective analysis of more than 9,300 patient cases, researchers found 31 of 144 medium-to-large polyps subjected to discordant-readings review proved out CT colonography’s positive findings over colonoscopy’s negatives.

That’s some 40 percent, and it’s especially striking since the endoscopists had knowledge of the CT colonographic findings going in.

From this and additional data the study’s authors, led by radiology resident B. Dustin Pooler, MD, reported ahead of print in Radiology that discordant polyps—those detected with CT colonography but not confirmed with subsequent colonoscopy—“require secondary review and consideration for follow-up because many ultimately prove to be clinically significant lesions.”

Unsurprisingly, the team found that colonoscopy false negatives were most prevalent in the hard-to-navigate right colon.

Meanwhile, 81 percent of colonoscopy false-negative lesions that were ultimately resected (21 of 26) were adenomas or serrated lesions. Of these, 43 percent (nine of 21) were characterized as advanced lesions, and 89 percent (eight of nine) of advanced lesions occurred in the right colon.

In the study, lesions missed in colonoscopy despite a priori knowledge of their size, location and morphologic structure with CT colonography were, on average, larger than 8 mm in diameter.

They were also more likely to be called “with higher diagnostic confidence with the initial CT colonography examination,” the authors write, adding that their findings should help point the way to improving colorectal cancer-screening strategies.

Read the full study.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.